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Abstract
Periodontal disease is an infectious and inflammatory disease with a high 
incidence in the global population and an extremely complex etiopathogenesis. 
Osteoporosis is one of the systemic diseases that can affect the integrity of peri-
odontal tissues. Osteoporosis, as a skeletal disease, causes a reduction in bone mass 
and microarchitectural changes in the bone. Discussions about the connection 
between the two diseases affecting the bone began in 1960, but, contrary to the high 
number of studies, discoveries are still being made regarding the pathophysiologi-
cal mechanisms that link the two diseases. The chapter proposes a systematized 
description of data on the influence of osteoporotic disease on the periodontal 
structures, therapeutic methods to address the patient with periodontal disease and 
osteoporosis and data on the potential influence of conventional and adjunctive 
periodontal treatment on systemic parameters in patients with osteoporosis.
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1. Introduction
In systemic diseases that can generate periodontal effects, it is worth mentioning 
osteoporosis as a separate entity in diseases of endocrine origin. Osteoporosis, as 
a skeletal disease, is characterized by reduced bone mass and micro-architectural 
changes in the bone that lead to bone fragility and an increased risk of fracture.
Bone tissues are dynamic, with healthy bone undergoing lifelong shaping and 
reshaping. Modelling is a process by which bone grows linearly in size in response to 
the stress applied to it. This involves bone neo-formation independent of a previous 
bone resorption, the skeleton being able to acquire new cortical shapes and thick-
nesses. On the other hand, remodelling is initiated by resorption and is followed 
by the formation of new bone tissue at the same resorption site. Bone remodelling 
repairs skeletal micro-destruction to preserve resistance and provides serum skel-
etal calcium for mineral homeostasis. Signals from mechanical stress are received 
by osteocytes and are transmitted to osteoclasts or osteoblasts or their precursors. 
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Bone resorption reflects the amount of osteoclast recruitment and death, as well as 
the rate of matrix degradation [1].
Hypothetical patterns linking the two conditions exist: it is assumed that 
reduced bone density in connection with osteoporosis may accelerate the resorption 
of alveolar bone caused by periodontitis, facilitating the invasion of pathogenic 
bacteria. This bacterial invasion affects normal bone homeostasis, increases osteo-
clastic activity, and reduces bone density both systemically and locally through both 
the direct effect of releasing toxins and the release of inflammatory mediators [2].
Since periodontal disease is a multifactorial condition, osteoporosis, although 
it may not be the cause of its onset, may be a factor in further exacerbation. Thus 
there is a greater predisposition to lose alveolar bone in subjects with osteoporosis, 
especially against the background of a pre-existing periodontal disease [3].
Oestrogen deficiency leads to the production of several cytokines produced by 
immune cells (monocytes and macrophages) and osteoblasts. When challenges arise 
from plaque biofilm products, bone resorption factors such as lipopolysaccharides, 
and toxins, the host’s immune system produces several inflammatory cytokines 
that activate osteoclasts and cause bone resorption. The accumulation of bacterial 
plaque made up of periodontal bacteria seems to be necessary for a woman who is 
deficient in oestrogen to show changes such as loss of attachment and destruction of 
the alveolar bone.
The inflammatory response of the host to this biofilm starts the inflammatory 
cascade and can lead to a constant activation of proteinases and enzymes with the 
role of tissue degradation, leading to destruction of connective tissues, resorption 
of alveolar bone and finally bone loss, which explains the increased risk of peri-
odontal damage in menopausal women [4].
Oestrogen deficiency-induced osteoporosis, characterized by an imbalance 
between bone formation and bone resorption, is caused by elevated inflammatory 
cytokines such as tumour necrosis factor α (TNFα), interleukin 1 (IL-1), IL-6 and 
gamma interferon (IFN-γ) [5]. Studies have shown that inflammatory cytokines 
increase osteoclast activity and activate bone resorption. Therefore, anti-resorptive 
therapy is widely used in the management of osteoporosis. This type of treatment, 
however, only prevents additional bone loss while barely stimulating bone forma-
tion and reversing bone loss. A number of studies have shown that elevated levels of 
inflammatory cytokines cause deficits in osteogenesis in postmenopausal osteopo-
rosis and in inflammatory diseases such as arthritis and periodontitis [6].
2.  Periodontal clinical and radiological status in patients with 
periodontal disease and osteoporosis
To date, most studies focused on the relationship between periodontal disease 
and osteoporosis have been performed in small groups, with limited control of bias 
factors, with significant variations in defining the parameters of periodontal disease 
and osteoporosis; there are also few longitudinal studies that establish a temporal 
relationship.
Decreased systemic bone density in patients with osteoporosis, including the jaw 
bones, may provide circumstances of increased susceptibility of these patients to 
periodontal damage.
Orthopantomography can be used as a complementary examination of the 
patient with osteoporosis and periodontal disease, to assess the width of the man-
dibular cortex, the cortical mandibular angle, the cortical index and the degree of 
resorption of the alveolar ridge. We conducted a study on a group of 41 subjects, 
whose aim was to evaluate radiological parameters on digital orthopantomography 
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in patients with chronic periodontitis and osteoporosis, as well as to establish a  
correlation between them [7], bone mineral density and periodontal clinical param-
eters. For radiographic analysis we used digital orthopantomographs. The following 
determinations were made:
• Mandibular cortex thickness in the chin region (MCT)
• Panoramic mandibular index (PMI) - obtained by dividing the thickness of 
the mandibular cortex at the distance between the chin hole and the lower 
mandibular cortex
• Degree of resorption of the alveolar ridge (M/M ratio)
• Morphological classification of the lower mandibular cortex (C classes)
C1: normal bone cortex, with regular endo-osteal margin at both sides;
C2: moderately eroded bone cortex, with endo-osteal margin with semilunar 
defects;
C3: severely eroded bone cortex, with visibly porous endo-osteal margin.
The mean value of the plaque index was 1.21 ± 0.32. This index has been closely 
correlated with a C2 bone cortex class. A positive correlation was demonstrated 
between this index and the average loss of attachment. The mean value of the 
gingival index was 0.79 ± 0.21. This index was correlated with class C2 of bone 
cortex and with average loss of attachment. The mean value of the bleeding index 
was 2.3 ± 0.38, an index also correlated with class C2 of the bone cortex and loss 
of attachment. The mean value of the periodontal probe performed on all study 
participants was 4.72 ± 1.02 mm. There was no correlation between probing depth 
and bone resorption index [7].
The mean value of attachment loss was 4.35 ± 1.01 mm. There was a close posi-
tive correlation between the average loss of periodontal attachment and the C2 class 
of bone cortex. There was a negative correlation between mean attachment loss and 
bone resorption index. There was a link between the average loss of periodontal 
attachment and the plaque index, calculus index and gingival index [7].
A total of 58.7% of patients had 15–30 teeth remaining on the arches; 27.9% of 
the total number of examined patients had up to 15 remaining teeth and 13.4% of 
them - over 30 remaining teeth on the dental arches. A total of 36.5% of patients 
had loss of dental-periodontal units due to coronary dental lesions, 30.7% due to 
periodontal disease and 32.8% due to the association of carious lesions with peri-
odontal disease. Only 3.8% of all patients had intact dental arches. Third molars 
were not considered in the calculation.
Using a threshold level of 3 mm for cortical thickness, only 2 patients had MCT 
<3 mm. We noticed an association between the T score value and MCT; low values  
of the T score were correlated with low values  of cortical thickness (p < 0.05) [7].
We noticed that a decrease of MCT by 1 mm increases the risk of osteopenia/
osteoporosis by 43%. The p value for MCT was statistically significant (p = 0.033). 
Moreover, when the morphology class is C2 or C3 (moderate and severe ero-
sions), the age is increased and the MCT decreases to a statistically significant 
level (p < 0.05). A decrease of one millimetre of MCT increases the probability of 
moderately or severely eroded cortex by 96%. In terms of tooth loss, a one-unit 
increase in the number of missing teeth increases the probability of moderate or 
severe erosion by 6%.
Given that periodontal examination, along with performing oral radiographs are 
common procedures [8], the clinical significance for the observation of additional 
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risk factors for osteoporosis is extremely high, and questions regarding skeletal 
status may arise. General condition of the patient.
An important result in this study is given by the close correlation between local 
factors and the loss of periodontal attachment and bone tissue. Moreover, the loss of 
attachment was closely related to the bone resorption index.
The oral cavity and jaws are examined radiologically more frequently than any 
other part of the human body. Orthopantomographic radiography can be a useful 
means of screening in the diagnosis of osteoporosis, providing valuable information 
on the quality of the maxillary bone.
The radiograph does not allow the visualization of the periodontal infection, 
nor the migration of the junction epithelium in the initial periodontal lesion. 
However, the radiographic image reflects the status of the mineralized structures of 
the periodontium. Thus, radiography is indispensable for assessing bone loss and 
for establishing residual value.
Clinical measurements by periodontal examination do not always fully and 
accurately reflect tissue loss, nor is radiography sufficient to establish a positive 
diagnosis. Radiography provides the image of two-dimensional bone changes, as 
well as abnormalities of radiopaque structures (carious, endodontic, reconstruc-
tive lesions). Radiographic images frequently used in periodontology are given 
by retro-dental-alveolar radiography, orthopantomography, as well as bite-wing 
radiography.
The panoramic x-ray represents a complex projection of the maxillary bones and 
dental arches, with multiple super-positions and distortions that can be exacerbated 
by image capture errors. Moreover, orthopantomography (OPT) illustrates numer-
ous anatomical structures, in addition to the maxillary bones, which can represent 
interpretive challenges. In order to obtain a successful interpretation of panoramic 
radiographs, an understanding of the normal anatomy of the head and neck region 
and its radiologic aspects is absolutely mandatory.
Analysis of the density of the trabecular pattern of the maxillary bone, seen 
radiologically, showed that dense trabeculation is a strong indicator of increased 
mineral density, while thin trabeculation corresponds to low mineral density [9]. 
It is well known that in patients with osteoporosis the bone loss is not uniform 
and that the trabecular bone is earlier and more deeply affected than the cortical 
bone [10].
The mandible has a composition similar to the femoral neck [11], where frac-
tures are mainly caused by a cortical loss rather than a trabecular bone. Given 
that the jaw consists mainly of trabecular bone, it is possible that the bone density 
measured at this level is more closely related to osteoporotic disease. However, the 
lack of fixed reference points in the upper jaw (such as the chin hole in the jaw) 
makes the assessment of standard points at this level a challenge.
Osteoporosis can be diagnosed by observing tooth loss, thinning of the lower 
mandibular cortex, and by changes in the morphology of the endo-osteal margin of 
the cortex and trabecular bone [12].
Mandibular bone mass correlates with systemic skeletal bone mass in numerous 
studies. Horner and Devlin reported a relationship between mandibular cortical 
thickness and mandibular bone density [12]. Cortical thickness at the gonial angle 
was determined by panoramic radiographs on a group of 180 patients; for patients 
aged 15 to 69 years, this was relatively constant; in subjects over 60 years of age, a 
decrease was observed, more significant for women than for men [13].
Devlin and Horner [12] reported that a cortical thickness of 3 mm is most 
appropriate as a threshold value for bone densitometry. White et al. [14] consider 
that this threshold value is more recommended to be 4 mm. Klemetti et al. [15] 
reported that the 4 mm threshold is optimal but not sufficient in itself for an 
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optimal classification of subjects. In the present study we discovered values  below 
3 mm only on 3 radiographs; thus, we support the opinion of White et al. according 
to which, if panoramic radiographs are used, the threshold for cortical thickness is 
more appropriate at 4 mm [14].
As for quantitative computed tomography (QCT), it was first used to study the 
relationship between oral status and osteoporosis in 1989. Regardless of the tech-
nique used, the position of the sections and perspective should be documented by 
subsequent examinations to avoid the error of precision. The reported accuracy for 
QCT ranges from 1 to 3% for highly controlled settings and 4–5% for clinical set-
tings [16]. Also, the cost of computed tomography is quite high, so it is not recom-
mended only for a screening system in osteoporotic disease.
It has been demonstrated that mandibular cortex thickness can be a useful 
parameter to clinically assess metabolic bone loss and that a gonial thickness of less 
than 1 mm is an indicator of metabolic bone loss [12]. Dissemination of information 
on the prevention of osteoporosis produces a significant public effect for the imple-
mentation of appropriate ways to minimize the process of reducing bone mass.
3.  The role of TNFα in patients with periodontal disease and 
osteoporosis
The main mechanism by which TNFα contributes to the evolution of osteoporo-
sis is by disturbing the balance between bone resorption and bone formation [17]. 
Previously, TNFα blockade was considered to be an effective method to suppress 
and prevent bone resorption [18]. TNFα blockade significantly stimulated bone 
formation in mice.
We conducted a study of 46 postmenopausal female subjects in which we 
assessed the levels of TNFα in crevicular fluid and serum [19]. Subjects were 
divided into two groups: the Study Group - patients with osteoporosis and peri-
odontal disease (n = 24) and the Control Group - patients with periodically healthy 
periodically disease (n = 22).
Probing depth (PD), bleeding on probing (BOP), and clinical attachment loss 
(CAL) had significantly higher values in the study group than in the control group 
(p < 0.05) [19]. We could not observe any significant differences in the values  of the 
plate index between the groups.
All samples showed detectable levels of TNFα. Significantly high levels of TNFα 
were detected in both serum and GCF for the study group compared to the control 
group. Serum TNFα was positively correlated with BOP (p < 0.01). There were no 
significant correlations between probing depth, clinical attachment loss, plaque 
index, and TNFα levels. Serum TNFα levels were correlated with TNFα levels in 
crevicular fluid.
Maintaining the balance of proinflammatory and anti-inflammatory cytokines 
in the body is one of the manifestations of self-regulation [20]. Over the past 
decade, considerable evidence suggests that oestrogen prevents bone loss by block-
ing the production of proinflammatory cytokines, such as interleukin-1 (IL-1), 
IL-6, IL-10, tumour necrosis factor (TNF) α in the spinal cord and bone cells.
Cytokines are soluble proteins that can initiate, mediate, and control immune 
and inflammatory responses. It has been proposed that pro and anti-inflammatory 
cytokines contribute to various bone metabolic diseases, including periodontitis 
and postmenopausal osteoporosis [21]. Among pro-inflammators, TNFα has been 
reported to play a key role in periodontal bone destruction [22].
In our study we demonstrated significant differences in TNFα values  between 
the osteoporosis group and the control group. It can be suggested that increased 
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TNFα values  in GCF and serum contribute to the large number of B cells and T cells 
present in inflammatory periodontal tissues, increasing the destruction of peri-
odontal tissue [19].
The fact that the values  in the crevicular fluid were correlated with the serum 
values  clearly indicates the influence that the systemic status generates on the local 
status (periodontal, in the case of the present study).
Periodontal tissue destruction is closely related to the release of inflammatory 
mediators, such as TNFα. These mediators are able to aggravate the inflammatory 
response. It has been shown that the severity of periodontal disease is associated 
with their concentration in the crevicular fluid.
Some subjects may have a more pronounced inflammatory response to bacterial 
aggression, a response that depends on the quality and quantity of the bacterial 
flora, as well as systemic factors (heredity, certain infectious/inflammatory dis-
eases, osteoporosis, etc.).
Inflammatory cytokines can influence this delicate balance by promoting osteo-
clast differentiation and activation. Bone loss is thus attributed more to increased 
bone resorption than to reduced bone neo-formation, with osteoclasts being the 
main culprits.
4.  The implications of the IL-1α and IL-1β cytokines in patients with 
periodontal disease and osteoporosis
IL-1α and IL-1β are biologically more or less equivalent pleiotropic factors 
that act locally and systemically. Only a few functional differences between the 
factors have been described; only IL-1β appears to be constitutively expressed in 
the brain. Interleukin-1 is a potent stimulator of bone resorption in vivo; IL-1β 
has been shown to be the most potent stimulator of bone resorption in vitro. 
The mechanism by which IL-1β stimulates resorption involves the expression of 
RANKL in osteoblasts and indirect stimulation of osteoclastogenesis and bone 
resorption [23].
There are also indications that osteoclasts express interleukin-1 receptor I, which 
is important for osteoclast activity and survival by activating the PI3K/AKT and 
ERK pathways, a MyD88-dependent response, but not on TRIF [24].
We conducted a study of 38 postmenopausal female subjects with the purpose 
to investigate differences in IL-1α and 1β levels in GCF in patients with chronic 
periodontitis, with or without associated chronic disease (in the present study - 
osteoporosis) [25].
IL-1α was the most prevalent cytokine found in GCF and was detected in all 
sites studied. We noticed significantly higher differences in interleukin levels for the 
study group (patients with osteoporosis) compared to systemically healthy patients 
(p < 0.05).
In order to establish the possible clinical relevance of these observations, a cor-
relation analysis was performed between the clinical parameters and the total levels 
of cytokines in the test sites. Positive correlations were observed between IL-1α and 
1β levels with PPD and CAL [25].
In periodontal inflammation, IL-1β is mainly expressed by macrophages and 
dendritic cells, but gingival fibroblasts, periodontal ligament cells, and osteoblasts 
can also secrete IL-1β. Elevated levels of IL-1β as well as IL-1α in gingival crevicular 
fluid have been reported by several groups [26]. There are many clinical studies 
showing the importance of IL-1β for inflammation and destruction in rheumatoid 
arthritis and osteoarthritis, associated with periodontal damage [27].
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There are several reasons to believe that IL-1β could be an important mediator 
of the destruction of gingival connective tissue and periodontal ligament, as well as 
the resorption of alveolar bone. IL-1β is a potent stimulator of matrix metallopro-
teinase expression in fibroblasts and periodontal ligament cells [28].
The challenge in osteoimmunology is to determine the relative contribution of 
various components of the immune system to bone loss induced by ovariectomy 
and senile osteoporosis. These may also involve identical adjustment paths; how-
ever, in each system, there will be subtle differences in the net balance of local or 
systemic regulators, resulting in specific patterns of subsequent bone loss.
5.  Influence of hormone replacement therapy on periodontal parameters 
in patients with osteoporosis
Hormone replacement therapy (HRT) represents an attractive method to 
counterbalance hormonal changes. The aim of HRT is not only to avoid climac-
teric signs and symptoms but also to protect the patients from cardiovascular 
disease and osteoporosis complications [29]. Having in mind that oestrogen 
deficit is an important risk factor for osteoporosis, it is of high importance to 
consider the role of oestrogen in the association between periodontal lesions and 
osteoporosis [30].
We proposed a comparative assessment of periodontal status in postmeno-
pausal patients who were on hormone replacement therapy or not. The study 
was performed on a group of 23 female subjects, diagnosed with osteoporosis, 
aged between 50 and 62 years [30]. Subjects were divided into two groups. The 
first group, the study group, included patients undergoing hormone replacement 
therapy (n = 13); the control group included patients who did not follow this 
therapy (n = 10). The patients underwent periodontal clinical examination.
We noticed that the risk of tooth loss was similar for both groups but this risk 
shows a slight form of decrease with increasing treatment duration. Regarding the 
bleeding on probing, its value was approximately twice higher in patients without 
hormone replacement therapy, compared to the control group. The diagnosis of 
periodontal disease was higher in patients who did not receive replacement therapy 
than in those with HRT. In the group without hormone replacement therapy, we 
noticed more severe periodontal attachment losses than in the study group, with 
HRT. Moreover, the level of clinical attachment was proportional to the duration of 
hormone replacement therapy [30].
An important effect of low levels of oestrogen is the decrease in the inhibition of 
osteoclatogenesis, with a consequent increase in the activity of osteoclasts [31]. The 
result is a decrease in bone mass and bone resistance.
In vitro experiments indicate that neutrophil chemotaxis is reduced in the  
presence of low concentrations of estradiol. On the other hand, progesterone 
increases the chemotaxis of neutrophils, so any change in the balance of these 
hormones in plasma or gingival tissue can have a significant effect on neutrophil 
function in vivo [32].
Until recently, hormone replacement therapy was considered the only effective 
treatment recommended for the prevention of diseases associated with oestrogen 
deficiency [30]. After the publication of the Women’s Health Initiative results in 
2002 and 2004 [33], the use of HRT has become a complex debated issue. Women’s 
Health Initiative and other data from dedicated studies suggested that the potential 
risks associated with HRT (increased risk of breast cancer and severe cardiovascular 
disease) are in direct relationship with the regimen administered, dose, mode of 
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administration, age of the patient, associated disease, and duration of treatment 
[34]. Therefore, based on current data, the purpose, dose and regimen of HRT 
should be individualized, with a complex evaluation of each case [30].
Oestrogen has two key roles in bone health. First of all, the hormone is essential 
for the normal maturation of the bone and for ensuring the acquisition of miner-
als so as to reach an optimal bone mass. Second, oestrogen maintains bone mass 
throughout adulthood during remodelling processes. Oestrogen deficiency leads to 
a reduction in bone mass and damage to bone microarchitecture, the two being the 
main aspects of osteoporosis.
Oestrogen deficiency can cause bone loss by acting directly on bone cells that are 
involved in bone turnover and by decreasing the influence that oestrogen has on the 
intestines and kidneys that regulate extra-skeletal calcium levels.
Oestrogen deficiency contributes to the deterioration of bone microarchitecture 
and to the reduction of bone strength which is determined by bone geometry, 
cortical thickness, porosity, trabecular morphology. Bone remodelling results in the 
modification of major determinants of bone strength [35].
Oestrogen has been shown to stimulate osteoprotegerin (OPG) expression in 
human osteoblasts. The hormone can thus have an effect on bone metabolism 
through the surrounding soft tissue cells. Oestrogen has been shown to inhibit 
the formation of osteoclastic cells in cultures of fibroblasts in the periodontal 
ligaments and mononuclear cells in the peripheral blood. This inhibitory effect 
was not found in cultures with gingival fibroblasts. This observation suggests that 
they are not as sensitive to oestrogen without a clear biological mechanism. It is 
known that oestrogen exerts its effects through intercellular receptors; oestrogen 
receptor concentration is thus an important determinant of the cellular response 
to oestrogen.
The inhibitory effect of oestrogen on osteoclastic cell formation corresponds to 
previous research obtained either by osteoblast-induced osteoclast production or 
by bone marrow cells used as precursors. In addition, in vivo studies using ovariec-
tomized mice have shown that oestrogen deficiency has induced the presence of a 
large number of osteoclasts in the periodontium. The data thus suggest that oestro-
gen plays an important role in modulating osteoclast formation.
Another important finding was the increased number of osteoclast-like cells in 
cultures with periodontal ligament fibroblasts. These observations suggest a differ-
ence in the interaction between different osteoblast populations and mononuclear 
cells in peripheral blood.
Subsequent analysis of molecules that may be involved in the oestrogen 
inhibitory effect involved the evaluation of mRNA expression of RANKL, OPG, 
and oestrogen receptors. No effect of oestrogen on the expression of these genes 
was found in any population of fibroblasts. The data suggest that the oestrogen 
inhibitory effect on osteoclastic cells can be mediated independently of OPG 
and RANKL, being mediated by other compounds such as TGF β, TNFα, IL-1, 
IL-6, IL-7 [30].
There are studies that have shown that the risk of edentulous ridges is lower 
in patients following HRT [36, 37]; it was observed that HRT reduced the risk of 
edentulousness by 6% for each year of HRT [38]. The patients with osteoporosis 
present a significant decrease in alveolar ridge height in edentulous areas and loss 
of alveolar ridge height is associated with osteoporosis and osteopenia [6]. We 
demonstrated a higher number of teeth present in patients with hormone replace-
ment therapy [30]. However, teeth loss does not represent an ideal surrogate 
assessment for periodontal disease, as it can also be caused by carious lesions or 
traumatic events.
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6.  Effects of modulating inflammatory response therapy in patients with 
osteoporosis and chronic periodontitis
Mechanical removal of plaque and calculus from dental surfaces is considered 
the standard treatment for chronic periodontitis. Contrary to the spectacular 
evolution in the field of etiopathogenesis of periodontal disease, its treatment has 
changed very little, in principle. Scaling and root planing remain the “gold stan-
dard” of periodontitis treatment.
The importance of the host inflammatory response in periodontal pathogen-
esis presents the opportunity to explore new therapeutic strategies by means of 
modulating this response. Modulation therapy can be combined with conventional 
therapeutic methods to reduce the bacterial load.
To date, the only systemic therapy approved as a modulator of the response 
in periodontal disease is with sub-antimicrobial doses of doxycycline, which 
inhibits the activity of matrix metalloproteinases (MMPs) (trade name: Periostat). 
Doxycycline in sub-antimicrobial doses inhibits MMP activity by synergistic 
mechanisms, independent of antibiotic properties. Primary studies have shown 
that the use of tetracycline predominantly inhibits MMPs in excess of periodontitis 
compared to constitutional MMPs. In vitro studies have shown that MMP-13 is 
more sensitive to tetracycline inhibitory concentrations than MMP-8 and MMP-1 
(fibroblastic collagenase) is the least sensitive.
Doxycycline has been shown to be more effective than other tetracyclines in 
reducing collagenase activity in crevicular fluid in patients with chronic peri-
odontitis [39]. Doxycycline has a lower inhibitory concentration than minocycline 
(IC50 = 15 IM compared to IC50 = 190IM) or tetracycline (IC50 = 350IM); thus, a 
lower dose of doxycycline than minocycline or tetracycline is required to reduce a 
certain level of collagenase by 50% [40]. Moreover, doxycycline is more effective 
in blocking the activity of neutrophil collagenase (MMP-8) than the activity of 
MMP-1 (fibroblastic collagenase), demonstrating that its use is a safe way to reduce 
pathological collagenase levels without affecting healthy tissues.
We conducted a study in a group of 26 subjects, with the purpose to analyse 
changes in periodontal clinical parameters that modulation therapy of the host 
response with sub-antimicrobial doses of doxycycline can exert in patients with 
periodontal disease and osteoporosis. Patients were randomly divided into two 
groups: the study group (n = 17), which underwent classical debridement therapy 
(scaling and root planing) plus sub-antimicrobial doses of doxycycline (20 mg 
twice daily) for 3 months, and control group (n = 18), which followed only classical 
debridement therapy [41].
We analysed the following periodontal parameters: probing depth, level of clini-
cal attachment, PBI and PI index at baseline (pre-therapeutic), on the last day of 
medication, and 3 months after medication completion (6 months from baseline). 
The sites were grouped according to the probing depth in: group 1 - superficial 
(0-3 mm); group 2 - moderate (4-6 mm) and group 3 - deep (≥7 mm) [41].
In the present study, 30 patients were initially enrolled, but 4 of them failed 
to complete doxycycline therapy. Therefore, the study resulted in the use of two 
groups: the study group (13 subjects) and the control group (13 subjects). There was 
no statistically significant difference between groups at baseline in terms of probing 
depth. No significant differences were observed in the sites with an initial depth of 
0–3 mm (p > 0.05). Significant reductions in probing depth were observed at sites 
with an initial depth of 4-6 mm and ≥ 7 mm (p < 0.025) [41].
Although the mean value of pocket reduction for sites with an initial depth of 
4-6 mm and ≥ 7 mm was higher for the study group than for the control group 
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(1.80 mm versus 1.46 mm for moderate pockets and 3.38 mm versus of 2.57 mm for 
deep pockets), the difference did not reach the significance threshold (p > 0.05). 
Analysis of sites with an initial depth ≥ 7 mm showed that an increased percent-
age of sites was reduced by at least 3 mm following doxycycline administration 
(66.4%), compared to the group without modulation therapy (55.1%) at 3 months, 
without a statistically significant difference between groups (p > 0.05) [41].
However, at 6 months the percentage of sites with an improvement in 
depth ≥ 3 mm was significantly higher (p = 0.011) for the group with modulation 
therapy (73.4%) compared to the group that followed only classical therapy (49.7%) 
[41]. At baseline, there were no statistically significant differences in the level of 
clinical attachment in the sub-grouped sites by probing depth between the main 
study groups (p > 0.05). Sites with moderate depths and deep sites showed signifi-
cant improvements in attachment level at 3 and 6 months, compared to baseline 
(p < 0.025). Sites with an initial depth of 0–3 mm did not show significant changes 
in attachment during the study period (p > 0.05) [41].
Sites with an initial depth of 0–3 mm in the control group (without doxycy-
cline therapy) showed a slight decrease in attachment (−0.04 mm at 3 months, 
−0.03 mm at 6 months). On the other hand, the sites with the initial depth 
of 0-3 mm in the study group showed a slight gain of attachment (0.11 mm at 
3 months, 0.14 mm at 6 months), but without significant differences between 
groups (p > 0.05).
Although the average attachment gains for sites with an initial depth of 4-6 mm 
and ≥ 7 mm was higher for the study group than for the control group (1.12 mm 
compared to 0.78 mm for sites with moderate depths; 2.15 mm compared to of 
1.76 mm compared to the deep sites), the statistical analysis did not show a level of 
significance (p > 0.05) [41].
GDP and PI values  showed significant improvements between baseline and re-
evaluations at 3 and 6 months (p < 0.025). The reduction in GDP and IP was similar 
for both groups (p > 0.05).
Periodontal treatment, over time, has focused on reducing the bacterial load 
and disorganizing the biofilm by mechanical methods. However, recent research 
has led to a paradigm shift in the evolution of periodontal disease. Thus, it is known 
today that the lesions that appear at the level of superficial and deep periodontal 
tissues are a result of the activation of the host’s immune-inflammatory defence 
mechanisms [42].
In addition to the classic periodontal therapy, scaling and root planing, which 
aims to disorganize the bacterial biofilm and reduce the inflammatory load, new 
adjunct methods have been postulated, with etiological therapeutic effect in the 
periodontopathic patient. Among them, the modulation therapy of the host’s 
inflammatory response with pharmacological agents has acquired important 
dimensions, precisely because of its effectiveness. The success of such therapy is all 
the more important as it affects a systemically affected area.
Doxycycline has the ability to inhibit the activity of matrix metalloproteinases 
(MMPs), a capacity confirmed in numerous studies. Minocycline, doxycycline, and 
tetracycline inhibit collagenolytic activity, while non-tetracycline antibiotics have 
no effect on collagenase [40]. It was recognized in the mid-1980s that inhibition of 
collagenolysis by tetracyclines is a new therapeutic method in the management of 
periodontal disease.
The effects of doxycycline are, in addition to direct inhibition of active matrix 
metalloproteinases by cationic chelation and inhibition of oxidative activation of 
latent MMPs, and inhibition of the expression of inflammatory cytokines (IL-1, 
IL-6, TNFα) and PG-E2; seeks and inhibits the formation of oxygen-reactive spe-
cies produced by neutrophils; protects the α1-proteinase inhibitor, thus indirectly 
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reducing tissue proteinase activity; reduces osteoclastic activity and bone resorp-
tion; inhibits osteoclastic MMPs.
Doxycycline contributes to decreased conjunctival lysis by inhibiting pro-
inflammatory mediators and cytokines (including IL-1 and TNFα) [43], as well as 
by increasing collagen production, osteoblast activity and bone formation [41]; this 
last aspect is of major importance especially for patients with osteoporosis, whose 
bone capital is affected.
A major concern with long-term administration of doxycycline has been associ-
ated with the development of antibiotic resistance. Indeed, when antimicrobial 
doses of tetracycline were used (250 mg daily, 2–7 years), up to 77% of patients’ 
flora showed resistance to tetracycline [44]. Given this problem, sub-antimicrobial 
doses (20 mg doxycycline versus 50 or 100 mg) were prepared [41]. One of the 
preliminary experiments with this new formula clearly demonstrated that such 
doses (20 mg twice daily), administered 2 weeks, inhibited collagenase activity by 
60–80% in gingival tissue in patients with chronic periodontitis [41]. Collagenase 
activity was significantly reduced in the crevicular fluid collected from these 
patients. Subsequent studies have indicated that this drug regimen can prevent 
the progression of periodontitis without the patient developing microorganisms 
resistant to doxycycline or other types of side effects [42].
The 3-month doxycycline regimen was well tolerated and no adverse reactions 
(gastrointestinal disorders, etc.) were reported. This may suggest that doxycy-
cline modulation therapy is a safe approach in the long-term treatment of chronic 
periodontitis.
In the present study we observed improvements in clinical parameters (probing 
depth, level of clinical attachment, bleeding index, plaque index) both for the study 
group (with adjunctive modulation therapy) and for the control group (which 
followed only classical scaling-root planing therapy), improvements that were 
maintained throughout the study.
Caton et al. [45] established that reductions in probing depth of at least 3 mm 
represent relevant, clinically significant improvements. In the present study, the 
percentage of sites of great depth (≥7 mm) that showed reductions of at least 3 mm 
was significantly higher at 6 months for the group with modulation therapy. This 
result is of special importance, given that sites with such depth are candidates for 
surgical procedures. Therefore, it can be hypothesized that adjunctive doxycycline 
therapy may reduce the likelihood of surgical procedures as well as the discomfort 
caused by them [41].
We also demonstrated that the sites with relatively small depths (0-3 mm) 
in the study group showed a slight gain of attachment, while these sites in the 
control group showed a slight loss of attachment. This supports the efficacy of 
host response modulation therapy by administering sub-antimicrobial doses of 
doxycycline.
Studies are needed to evaluate the efficacy of very long-term sub-antimicrobial 
doses of doxycycline in periodontal therapy and in the prevention of loss of dental-
periodontal units. The financial benefit derived from adjunctive therapy must 
also be evaluated (can this minimize costs by avoiding the need for periodontal 
surgery?).
It is suggested that doxycycline-based products be developed to support plasma 
concentrations for 24 hours by administering a single dose daily.
Given the increased variability of pathogenic pathways with a role in periodontal 
destruction (e.g., the cytokine group IL-1 is much more complex today), a more 
diverse range of host response modulators is also needed [46]. Moreover, most bio-
logical responses involve a variety of mechanisms; thus, blocking a single inflam-
matory pathway may not result in the desired result because receptor-mediated 
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responses can be activated by alternative pathways. Therefore, a poly-pharmaceu-
tical approach is needed to modify a number of different pathways associated with 
inflammation and tissue destruction.
Lipoxins are another group of compounds that can alter the inflammatory 
response in periodontal tissue. These mediators are released during the inflamma-
tory response and have the effect of decreasing inflammation and modulating its 
disappearance. Lipoxins block the secretion of IL-1β from neutrophils and block the 
migration of neutrophils following exposure to Porphyromonas gingivalis [47].
Osteotrophic factors such as hormonal or endocrine-related (vitamin D3, 
parathyroid hormone), cytokines (IL-1, IL-6, IL-11 and IL-17), growth factors 
(TNFα, morphogenetic protein-2) and others molecules (PG-E2, LyT activator 
CD40 ligand and glucocorticoids) increase the expression of the RANKL gene in 
osteoblastic/stromal cells.
Sequentially, RANKL mediates the signal for ostoclastogenesis through RANK or 
preosteoclastic cells. Thus, the RANKL/RANK interaction is responsible for the dif-
ferentiation and maturation of osteoclast precursor cells with osteoclast formation. 
Osteoprotegrin acts by binding to RANKL, inhibiting osteoclastic development.
In periodontal disease the first to investigate the role of RANKL in bone resorption 
was Teng [48]. It inoculated Aggregatibacter actinomycetemcomitans in mice lacking 
endogenous LyT and LyB and receiving human CD4 cells; Thus, CD4 + activation, 
RANKL stimulation and bone resorption were initiated, concluding that RANKL 
expression plays a significant role in bone destruction in periodontitis. Crotti et al. 
[49] observed a hyper-expression of RANKL in inflamed periodontal tissues, as well 
as an increased RANKL/osteoprotegrin ratio to healthy subjects.
There are numerous animal studies as well as preliminary human studies dem-
onstrating inhibition of RANKL function by osteoprotegrin treatment, reducing 
the number of osteoclastic cells and, implicitly, bone resorption from periodontal 
disease. Of course, more in-depth studies are needed to certify the most effective 
therapeutic approach to this molecular interaction.
Fatty acids have been proposed to reduce chronic inflammation in arthritis 
patients by decreasing the release of LTB4 from neutrophils and IL-1 from mono-
cytes. Local application of Omega-3 polyunsaturated fatty acids has been success-
ful in patients with inflammatory diseases such as psoriasis, as well as in models 
with experimental periodontitis in animals. The mechanism of action is based on 
decreased leukocyte chemotaxis, expression of molecular adhesion and production 
of inflammatory cytokines. Offenbacher demonstrated the inhibition of PG-E2 
production by eicosapentanoic or docosahexanoic acid administration, with effects 
similar to ibuprofen in patients with periodontal disease [50].
Vardar evaluated the use of omega-3 fatty acids in order to block arachidonic 
acid cascade in mice with experimentally induced periodontal disease [51]. This 
would inhibit the production of cyclooxygenase-derived prostanoids and lipo-
oxygenase-derived leukotrienes. The authors relied on two aspects: leukotriene 
B4 (mediator of arachidonic acid) plays an important role in bone resorption and 
inhibition of COX with NSAIDs would cause the accumulation of arachidonic acid 
that is metabolized by lipo-oxygenase, causing continuous bone loss. The authors 
also administered a combination of omega-3 fatty acids with celecoxib, seeking a 
synergistic anti-inflammatory effect. Combination therapy resulted in significant 
decreases in prostaglandin, leukotriene B4 and PAF levels; no effect on bone lysis 
was observed (this may be due to the short evaluation period).
Elkhouli published the results of a study of 40 patients with at least one grade II 
furcation defect; patients were divided into two groups: the first group performed 
allografting, which was associated with therapy with omega-3 polyunsaturated 
fatty acids and low-dose aspirin; in the second group (control) only allografting 
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was performed, following a placebo adjunctive therapy. At 3 and 6 months, the 
clinical parameters (plaque index, gingival index, bleeding index, probing depth, 
level of clinical attachment) were evaluated, as well as biochemical markers in the 
crevicular fluid (IL-1b and IL-10) [52]. The results were very good for the test group 
compared to the control group (reduction of probing depth, gain of clinical attach-
ment, significant modulating effect for IL-1b and IL-10 levels).
There are proven clinical results regarding monounsaturated fatty acid substitu-
tion; they influence blood pressure, clotting, endothelial activation, inflammation 
and thermogenic capacity in cardiac patients, they prevent obesity and other 
metabolic diseases.
Hasturk demonstrated in a study in rabbits with experimentally induced peri-
odontitis with Porphyromonas gingivalis that topical application of the tetradeca-
nol-1 complex (1-TDC: mixture of esterified monounsaturated fatty acids) causes 
an inhibitory effect on the inflammatory cascade of the host response [53].
Further studies are needed to evaluate the impact of this modulation therapy in 
patients with periodontal disease and osteoporosis at the molecular level (by exami-
nation of the crevicular fluid), on pro-inflammatory cytokines, and at the systemic 
level, by assessing bone mineral density (correlation with pre- and post-therapeutic 
T score).
7. Conclusions and perspectives
Chronic periodontitis and osteoporosis are two chronic diseases, with inflam-
matory etiopathogenesis, whose statistical characteristics are constantly growing 
worldwide. Studies focused on the association of these diseases in the same subjects 
are few and with discordant results. These may be due to the variability of the 
inclusion/exclusion criteria, the research methodology, as well as the small groups 
of subjects included.
The research supports the role that a routine operation performed in the dental 
office - panoramic radiography - could play in detecting undiagnosed cases of 
osteoporosis, given the local changes that occur in such patients. Signs of periodon-
tal tissue destruction are also reflected radiologically, where the thickness of the 
mandibular cortex and the morphological appearance of the cortex (presence of 
erosions) have been shown to be closely correlated with the value of the densito-
metric T Score. Therefore, orthopantomography, a common procedure in the dental 
office, could be an effective and less expensive method of screening for osteoporo-
sis, with a significant role for the dentist in this procedure.
Despite advances in research methodology and laboratory tests, in order to 
identify the factors associated with chronic periodontal disease, it is still unclear 
how to predict the progression of periodontal disease. Extensive research has been 
done in the area of  host biochemical response markers in periodontal disease. It 
is unlikely that a unitary biomarker will be able to meet the criteria for estimating 
future destruction from periodontal disease.
Patients with periodontal disease with osteoporosis had higher levels of TNFα, 
IL-1α, IL-1β, IL-6 and RANKL in the crevicular fluid, compared to systemically 
healthy patients. Also, cytokine values  were positively correlated with periodontal 
parameters. Therefore, it can be stated that these patients are prone to excessive 
production of this type of cytokine which also activates B cells and promotes B cell 
activity in periodontal inflammatory sites, aggravating the evolution of periodontal 
disease.
The conventional systemic hormone replacement therapy was associated with 
lower indices of gingival inflammation, such as a reduced gingival bleeding index 
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in subjects who followed hormone replacement therapy when compared to the 
subjects without HRT [30]. The risk of tooth loss was reduced in the group with 
HRT, when compared to patients without HRT and, more importantly, the number 
of present teeth is directly proportional to the duration of the substitution therapy 
[30]. The diagnosis of periodontal disease was more common in patients without 
hormone replacement therapy compared to those with HRT. We can conclude that 
HRT generates a positive effect on periodontal tissues, an effect that is all the better 
highlighted as hormone replacement therapy has a longer duration; still, this benefit 
needs to be carefully assessed and compared to the potential risks of such therapy 
[30]. These aspects bring in a new sphere the ways of complex and interdisciplinary 
therapeutic approach of patients with osteoporosis and chronic periodontitis.
We also proposed a unique analysis in the context of the association of the 
two diseases - periodontal disease and osteoporosis - of the effects generated by a 
deputy form of periodontal therapy, extremely topical, that of modulation therapy 
by chemotherapeutic agents of the host’s inflammatory response. We demonstrated 
in the study that adjunctive therapy with sub-antimicrobial doses of doxycycline 
(administration of 20 mg twice daily, 3 months), in combination with classical 
therapy, generated significant clinical improvements in patients with periodontal 
disease and osteoporosis - maintained during the study and that could pre-meet 
the need for surgery. We also demonstrated that sites with relatively small depths 
(0-3 mm) in the modulation therapy group showed a slight gain in attachment, 
while these sites in the control group showed a slight loss of attachment. This 
supports the efficacy of host response modulation therapy by administering 
sub-antimicrobial doses of doxycycline. Taken together, the data presented should 
inspire further research, providing epigenetic responses in periodontics, and using 
this information to develop future therapies.
The set of studies carried out supports in a complex way the importance of the 
bidirectionality of the periodontal disease - osteoporosis relationship, offering new 
information and protocols to approach patients, with certain value both for the 
medical community and, especially, for the entity that is at the centre of its concern 
- the patient per se.
Studies have shed new light on the link between periodontal disease (particu-
larly in its chronic form) and osteoporosis. The data obtained show observations 
of a clinical and paraclinical nature, which aim to expand the knowledge related to 
this complex association, with practical applicability, which supports the concept of 
interdisciplinary approach to the patient.
Periodontal tissue damage, clinically detectable by measurements of periodontal 
parameters (probing depth, loss of clinical attachment, probing bleeding), is more 
severe in patients with osteoporosis than in systemically healthy patients. Research 
has shown that osteoporosis systemically creates favourable circumstances for the 
evolution of periodontal disease, but it is also significantly associated with local 
determinants and factors.
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